化膿性汗腺炎市場 - KOL的考察

本報告提供化膿性汗腺炎市場相關調查分析，對已上市的治療方法和開發平台有的治療方法的KOL的考察。

目錄

摘要整理

治療流程

調查目的

已上市/仿單標示外的治療方法

• 抗腫瘤壞死因子TNF製劑
  • 修美樂（阿達木單抗；艾伯維）
  • Remicade（英夫利西單抗；Janssen/Merck & Co.）

管道療法

• IL-17抑制劑
  • Cosentyx（蘇金單抗；諾華）
  • Bimzelx（bimekizumab；UCB）
  • Izokibep（Acelyrin）
  • Sonelokimab（MoonLake 免疫療法）
• IL-36抑制劑
  • Spevigo（spesolimab；勃林格殷格翰）
• JAK抑制劑
  • Povorcitinib（INCB54707；Incyte）
  • Jakafi/Jakavi（魯索替尼；Incyte）
  • Rinvoq（upadacitinib；艾伯維）
• JAK/TYK 抑制劑
  • Brepocitinib（Priovant/輝瑞）
• 補體 C5a 抑制劑
  • Vilobelimab (InflaRx) 與 avacopan (Tavneos; Amgen/Vifor Fresenius)
• PDE4抑制劑
  • 奧司司特（UNION 療法）
• 趨化因子 (CXCR1/2) 抑制劑
  • LY3041658（禮來）
• IL-1抑制劑
  • Lutikizumab（ABT-981；艾伯維）
• 其他作用機制
  • 重要考慮因素摘要

熱射病管理的治療動態

• 重要考慮因素摘要
  • 多項藥物獲批為 KOL 提供了更好的 HS 治療選擇：抗 IL17 療法看來可能已站穩腳跟

HS市場前景與演變

• 重要考慮因素摘要
  • 疾病異質性和晚期疾病診斷是熱射病治療中的一些挑戰

附錄

KOL突發新聞

Expect significant and much needed expansion of therapy options in the HS treatment sector. Will Abbvie's Humira/biosimilar adalimumab maintain its first-line position? How do KOLs assess anti-IL17 drugs and why do they say that UCB's Bimzelx has an edge on Novartis' Cosentyx? Why are experts enthusiastic about oral JAK inhibitors, despite safety concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area:

• 21 Sep 2023 KOL Bulletin -- Views on top-line results from the Phase IIb/III trial of Acelyrin's izokibep in moderate-to-severe HS

Table of Contents

Executive summary (2)

Treatment algorithm (2)

Research objectives (1)

Marketed and off-label therapies (8)

• Anti-tumour necrosis factor TNF agents (8)
  • Humira (adalimumab; AbbVie) (8)
  • Remicade (infliximab; Janssen/Merck & Co.)

Pipeline therapies (47)

• IL-17 inhibitors (17)
  • Cosentyx (secukinumab; Novartis) (8)
  • Bimzelx (bimekizumab; UCB) (4)
  • Izokibep (Acelyrin) (3)
  • Sonelokimab (MoonLake Immunotherapeutics) (2)
• IL-36 inhibitors (1)
  • Spevigo (spesolimab; Boehringer Ingelheim) (1)
• JAK inhibitors (12)
  • Povorcitinib (INCB54707; Incyte) (6)
  • Jakafi/Jakavi (ruxolitinib; Incyte) (3)
  • Rinvoq (upadacitinib; AbbVie) (3)
• JAK/TYK inhibitor (1)
  • Brepocitinib (Priovant/Pfizer) (1)
• Complement C5a inhibitors (4)
  • Vilobelimab (InflaRx) and avacopan (Tavneos; Amgen/Vifor Fresenius) (4)
• PDE4 inhibitor (3)
  • Orismilast (UNION therapeutics) (3)
• Chemokine (CXCR1/2) inhibitor (3)
  • LY3041658 (Lilly) (3)
• IL-1 inhibitor (3)
  • Lutikizumab (ABT-981; AbbVie) (3)
• Other mechanisms of action (3)
  • Key insights summary (3)

Treatment dynamics for the management of HS

• Key insights summary
  • Multiple drug approvals will provide KOLs with better treatment options for HS: anti-IL17 therapies will become firmly established

Outlook and evolution of the HS market (1)

• Key insights summary (1)
  • Disease heterogeneity and late disease diagnosis comprise some of the challenges in the treatment of HS (1)

Appendix

• KOL details
  • KOLs from North America
  • KOLs from the Europe

KOL Bulletins (1)